Clostridium Difficile Infection
Conquering C. Difficile Associated Diarrhea with Probiotics
According to a recent study published by the Cochrane Library, the administration of probiotics to those at high-risk of developing C.difficile-associated diarrhea (CDAD) reduced a patient’s risk by 70%. This finding provides a low-cost, non-invasive option for reducing incidences of CDAD and the associated patient suffering. But the effectiveness of the treatment requires the early identification of at-risk patients who could benefit from probiotics. This is where the Jvion Machine is bridging the gap between new treatments and at-risk populations.
The patient population at high-risk of developing CDAD comprises 15% of the total patient population. These individuals are at more than 10% risk of developing the infection with an overall incidence rate of 1.7%.
The Jvion Machine is able to correctly identify 95% of all CDAD cases in the 15% of the population where the risk is greater than 10%. For a medium-size hospital with a patient population of 20,000, 3,000 patients would be at high-risk, and of those 323 would develop CDAD. If probiotics are administered to the high-risk population, it stands to reason that 226 or (70%) of these incidences could be prevented.
Probiotics cost $24 per patient. Using the Jvion Machine, we can target the administration of these probiotics to the 15% of the population at high-risk of an infection. The total spend of the intervention across all 3,000 patients comes to $72,000. The cost estimate per CDAD episode cited within the Cochrane study is $7,286. By preventing the anticipated 226 cases of CDAD, we would avoid $1,646,636 in costs. The total cost savings after accounting for the cost of treatment is $1,574,636. And this is all enabled by the ability to identify who is on a trajectory toward CDAD risk, providing the right information on the contributors to that risk, and enabling the clinical action that will lead to the best possible outcomes—in this case probiotics.
Dr. Karin Molander MD, FACEP, is the chair-elect of the Sepsis Alliance Board of Directors and se...